244 related articles for article (PubMed ID: 9342060)
1. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study.
Lorenzi P; Yerly S; Abderrakim K; Fathi M; Rutschmann OT; von Overbeck J; Leduc D; Perrin L; Hirschel B
AIDS; 1997 Oct; 11(12):F95-9. PubMed ID: 9342060
[TBL] [Abstract][Full Text] [Related]
2. Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
Cameron DW; Japour AJ; Xu Y; Hsu A; Mellors J; Farthing C; Cohen C; Poretz D; Markowitz M; Follansbee S; Angel JB; McMahon D; Ho D; Devanarayan V; Rode R; Salgo M; Kempf DJ; Granneman R; Leonard JM; Sun E
AIDS; 1999 Feb; 13(2):213-24. PubMed ID: 10202827
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
[TBL] [Abstract][Full Text] [Related]
5. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
[TBL] [Abstract][Full Text] [Related]
6. Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients.
Battegay M; Vernazza PL; Bernasconi E; Flepp M; Sendi P; Erb P; Malinverni R; Jaccard C; Morgenthaler S; Bedoucha V; Hirschel B;
HIV Med; 2001 Jan; 2(1):35-42. PubMed ID: 11737374
[TBL] [Abstract][Full Text] [Related]
7. The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.
Churchill DR; Pym AS; Galpin S; Foxall R; Stainsby C; Clarke JR; Kaye S; Bloor S; Larder BA; Wills B; Sun E; Babiker AG; Back DJ; Weber JN
AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1181-9. PubMed ID: 10480631
[TBL] [Abstract][Full Text] [Related]
8. Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.
Rolla VC; da Silva Vieira MA; Pereira Pinto D; Lourenço MC; de Jesus Cda S; Gonçalves Morgado M; Ferreira Filho M; Werneck-Barroso E
Clin Drug Investig; 2006; 26(8):469-79. PubMed ID: 17163279
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.
Ananworanich J; Kosalaraksa P; Hill A; Siangphoe U; Bergshoeff A; Pancharoen C; Engchanil C; Ruxrungtham K; Burger D;
Pediatr Infect Dis J; 2005 Oct; 24(10):874-9. PubMed ID: 16220084
[TBL] [Abstract][Full Text] [Related]
10. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals.
Kaufmann GR; Duncombe C; Cunningham P; Beveridge A; Carr A; Sayer D; French M; Cooper DA
AIDS; 1998 Sep; 12(13):1625-30. PubMed ID: 9764781
[TBL] [Abstract][Full Text] [Related]
11. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure.
Deeks SG; Grant RM; Beatty GW; Horton C; Detmer J; Eastman S
AIDS; 1998 Jul; 12(10):F97-102. PubMed ID: 9677159
[TBL] [Abstract][Full Text] [Related]
12. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study.
Rhone SA; Hogg RS; Yip B; Sherlock C; Conway B; Schechter MT; O'Shaughnessy MV; Montaner JS
AIDS; 1998 Apr; 12(6):619-24. PubMed ID: 9583602
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.
Zolopa AR; Shafer RW; Warford A; Montoya JG; Hsu P; Katzenstein D; Merigan TC; Efron B
Ann Intern Med; 1999 Dec; 131(11):813-21. PubMed ID: 10610625
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.
Kravcik S; Gallicano K; Roth V; Cassol S; Hawley-Foss N; Badley A; Cameron DW
J Acquir Immune Defic Syndr; 1999 Aug; 21(5):371-5. PubMed ID: 10458617
[TBL] [Abstract][Full Text] [Related]
15. Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
Marin-Niebla A; Lopez-Cortes LF; Ruiz-Valderas R; Viciana P; Mata R; Gutierrez A; Pascual R; Rodriguez M
Antimicrob Agents Chemother; 2007 Jun; 51(6):2035-42. PubMed ID: 17371813
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens.
Pellegrin I; Breilh D; Birac V; Deneyrolles M; Mercié P; Trylesinski A; Neau D; Saux MC; Fleury HJ; Pellegrin JL
Ther Drug Monit; 2001 Aug; 23(4):332-40. PubMed ID: 11477313
[TBL] [Abstract][Full Text] [Related]
17. Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.
Tebas P; Patick AK; Kane EM; Klebert MK; Simpson JH; Erice A; Powderly WG; Henry K
AIDS; 1999 Feb; 13(2):F23-8. PubMed ID: 10202820
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
19. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
20. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
Michelet C; Ruffault A; Sébille V; Arvieux C; Jaccard P; Raffi F; Bazin C; Chapplain JM; Chauvin JP; Dohin E; Cartier F; Bellissant E
Antimicrob Agents Chemother; 2001 Dec; 45(12):3393-402. PubMed ID: 11709314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]